کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9320397 | 1253258 | 2005 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The Current Status of Therapy for Symptomatic Late-Onset Hypogonadism with Transdermal Testosterone Gel
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: The Current Status of Therapy for Symptomatic Late-Onset Hypogonadism with Transdermal Testosterone Gel The Current Status of Therapy for Symptomatic Late-Onset Hypogonadism with Transdermal Testosterone Gel](/preview/png/9320397.png)
چکیده انگلیسی
An important concern among clinicians is that testosterone therapy may cause or promote prostate cancer. While current evidence supports the safety of testosterone therapy, androgens are growth factors for pre-existing prostate cancer. Therefore, before therapy is initiated, careful digital rectal examination and determination of prostate-specific antigen (PSA) in serum should be performed, in order to exclude evident or suspected prostate cancer. The first 3-6 months after initiating testosterone therapy is the most critical time for monitoring effects on the prostate. Therefore, it is important to monitor PSA levels every 3 months for the first year of treatment; thereafter, regular monitoring (mostly for prostate safety but also for cardiovascular and haematological safety) during therapy is mandatory.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Urology - Volume 47, Issue 2, February 2005, Pages 137-146
Journal: European Urology - Volume 47, Issue 2, February 2005, Pages 137-146
نویسندگان
T. Ebert, F. Jockenhövel, A. Morales, R. Shabsigh,